Scientists have developed a new gene therapy approach that offers promise for one day treating retinitis pigmentosa, according to Trinity College Dublin.
Researchers from Trinity College and University College London (UCL) teamed up to pool their expertise in genetics, virology, and ophthalmology, beginning the journey toward a new treatment for a group of eye diseases collectively referred to as retinitis pigmentosa (RP). Their results are published today in leading journal, Stem Cell Reports.
The collaborative team behind the new research used a modified common virus to deliver a normal, functioning copy of the RP2 gene into “mini retinas,” which had been engineered from stem cells and which contained the defective version of the gene. The “mini retinas” developed in UCL simulated the RP2 disease in patients.
Subsequent analysis showed that these mini retinas had successfully taken up the functioning RP2 gene following the viral delivery and produced the essential protein associated with it.
Crucially, the treated mini retinas showed significant improvement – underlining that the approach had rescued them from RP.
Ciara Shortall, PhD Researcher in Trinity’s School of Genetics and Microbiology, is one of the main authors of the published study. Explaining the significance of the work, she said:
“For the last 30 years there has been a lot of buzz about gene therapies and their potential for treating a huge variety of debilitating diseases and disorders, but it is really only recently that science has overcome difficulties associated with such approaches and begun to bring potential therapies far closer.
“In relative terms it is now fairly easy to replace troublesome genes with functioning versions using non-harmful viruses, which is what we have done here. And while we are still some time and a lot of work away from an approved therapy it is hugely exciting to have begun a journey that could one day provide an effective treatment to rescue eyesight.”
The Trinity team, led by Professor Jane Farrar, used their expertise in genetics and virus creation in the process, while the UCL team, led by Professor Michael Cheetham, took the lead in creating the mini retinas used to road-test the gene therapy.
“It is an important development that we can now reproduce so many elements of inherited disease using these mini-retinas. It makes it possible for us to study in detail why people go blind and try to find ways to prevent blindness. It’s exciting that the gene therapy seems to be so effective for this form of RP,” Professor Cheetham said in the news release.
Ocular research in Trinity College Dublin is supported by the Health Research Board of Ireland, Science Foundation Ireland, Fighting Blindness Ireland and Health Research Charities Ireland.